Janux Therapeutics, Inc. (NASDAQ:JANX) Receives $95.25 Average PT from Brokerages

Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) has received an average recommendation of "Buy" from the eleven brokerages that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $95.25.

Several research firms have recently commented on JANX. William Blair reissued an "outperform" rating on shares of Janux Therapeutics in a report on Friday, January 10th. Wedbush reiterated an "outperform" rating and issued a $76.00 price target (up previously from $75.00) on shares of Janux Therapeutics in a research note on Friday, February 28th. Scotiabank reduced their target price on Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating on the stock in a report on Friday, February 28th. Finally, HC Wainwright reissued a "buy" rating and set a $70.00 price target on shares of Janux Therapeutics in a research note on Monday, March 3rd.

Janux Therapeutics Trading Up 2.0 %

Janux Therapeutics stock traded up $0.65 during mid-day trading on Friday, hitting $33.20. The stock had a trading volume of 938,891 shares, compared to its average volume of 848,751. Janux Therapeutics has a one year low of $22.52 and a one year high of $71.71. The firm has a market capitalization of $1.96 billion, a P/E ratio of -28.38 and a beta of 3.27. The firm's 50 day moving average is $29.83 and its 200 day moving average is $42.82.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.36) earnings per share for the quarter, topping analysts' consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. As a group, equities research analysts forecast that Janux Therapeutics will post -1.38 earnings per share for the current year.

Insider Activity

In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 3,334 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $32.15, for a total value of $107,188.10. Following the sale, the insider now owns 82,139 shares in the company, valued at $2,640,768.85. This trade represents a 3.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Ra Capital Management, L.P. purchased 341,742 shares of the business's stock in a transaction dated Wednesday, March 5th. The stock was bought at an average price of $30.64 per share, for a total transaction of $10,470,974.88. Following the completion of the acquisition, the director now owns 9,658,988 shares of the company's stock, valued at approximately $295,951,392.32. The trade was a 3.67 % increase in their position. The disclosure for this purchase can be found here. Insiders sold 10,002 shares of company stock valued at $348,203 in the last ninety days. Insiders own 29.40% of the company's stock.

Institutional Investors Weigh In On Janux Therapeutics

Several large investors have recently added to or reduced their stakes in JANX. RA Capital Management L.P. raised its stake in shares of Janux Therapeutics by 13.1% during the fourth quarter. RA Capital Management L.P. now owns 10,365,652 shares of the company's stock valued at $554,977,000 after acquiring an additional 1,200,000 shares in the last quarter. Paradigm Biocapital Advisors LP raised its position in Janux Therapeutics by 46.5% during the 4th quarter. Paradigm Biocapital Advisors LP now owns 3,515,986 shares of the company's stock valued at $188,246,000 after purchasing an additional 1,115,412 shares in the last quarter. Janus Henderson Group PLC lifted its holdings in shares of Janux Therapeutics by 41.2% in the 4th quarter. Janus Henderson Group PLC now owns 3,562,402 shares of the company's stock worth $190,617,000 after buying an additional 1,038,996 shares during the period. Adage Capital Partners GP L.L.C. grew its position in shares of Janux Therapeutics by 47.6% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 3,061,750 shares of the company's stock worth $163,926,000 after buying an additional 986,750 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its stake in shares of Janux Therapeutics by 596.3% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,109,978 shares of the company's stock valued at $59,429,000 after buying an additional 950,557 shares during the period. 75.39% of the stock is owned by hedge funds and other institutional investors.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.